- Furthers Baxter’s continued innovation in medication delivery and management
- Integrates Baxter’s decades of leadership in infusion therapy with innovative digital health solutions to build on the company’s proven technology for helping to protect infusions from medication errors
- Supports neonatal and pediatric clinicians and anesthesiologists to help provide safe, accurate infusions for vulnerable patients
Phillips 66 Earnings Beat Expectations, Announces $5 Billion Buyback Authorization
Phillips 66 (NYSE: PSX) reported an adjusted EPS of $4.63 for the third quarter (Q3) of 2023.